Cara Therapeutics Inc.
| NASDAQ: CARA | Healthcare / Biotechnology / USA |
| 1.13 | +0.0800 | +7.62% | Vol 490.70K | 1Y Perf -91.48% |
| Dec 6th, 2023 16:00 DELAYED |
| BID | 1.10 | ASK | 1.17 | ||
| Open | 1.06 | Previous Close | 1.05 | ||
| Pre-Market | - | After-Market | 1.17 | ||
| - - | 0.04 3.54% |
| Target Price | 22.33 | Analyst Rating | Moderate Buy 1.75 | |
| Potential % | 1.88K | Finscreener Ranking | ★★★★ 53.61 | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★★ 56.19 | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★ 59.23 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 1.93 | Earnings Rating | Strong Sell | |
| Market Cap | 61.56M | Earnings Date | 13th Nov 2023 | |
| Alpha | -0.04 | Standard Deviation | 0.18 | |
| Beta | 0.81 |
Today's Price Range 1.051.16 | 52W Range 0.900012.80 | 5 Year PE Ratio Range -6.10164.70 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 16.87% | ||
| 1 Month | -8.87% | ||
| 3 Months | -42.93% | ||
| 6 Months | -66.67% | ||
| 1 Year | -91.48% | ||
| 3 Years | -92.47% | ||
| 5 Years | -92.97% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -23.44 | |||
ROE last 12 Months | -49.13 | |||
ROA (5Y Avg) | -15.73 | |||
ROA last 12 Months | -43.80 | |||
ROC (5Y Avg) | -45.67 | |||
ROC last 12 Months | -44.43 | |||
Return on invested Capital Q | -11.75 | |||
Return on invested Capital Y | -15.09 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 6.60 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -6.40 | ||||
| 3.11 | ||||
| 14.00 | ||||
| 25.00 | ||||
| -10.40 | ||||
| -1.06 | ||||
| 3.11 | ||||
| 3.44 | ||||
| 421.17M | ||||
| Forward PE | -0.67 | |||
| PEG | -1.25 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.90 | ||||
| 6.60 | ||||
| 0.00 | ||||
| 0.01 | ||||
| - | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 87.00 | ||||
| -227.60 | ||||
| -227.00 | ||||
| -2 310.90 | ||||
| 17.76 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 38.61M | ||||
| 0.72 | ||||
| 18.01 | ||||
| 121.54 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.53 | -0.52 | 1.89 |
| Q02 2023 | -0.56 | -0.58 | -3.57 |
| Q01 2023 | -0.53 | -0.49 | 7.55 |
| Q04 2022 | -0.33 | -0.56 | -69.70 |
| Q03 2022 | -0.42 | -0.43 | -2.38 |
| Q02 2022 | -0.28 | -0.08 | 71.43 |
| Q01 2022 | -0.56 | -0.52 | 7.14 |
| Q04 2021 | -0.50 | -0.63 | -26.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | -0.57 | -46.15 | Negative |
| 12/2023 FY | -2.07 | -10.70 | Negative |
| 3/2024 QR | -0.48 | -9.09 | Negative |
| 12/2024 FY | -1.56 | -50.00 | Negative |
| Next Report Date | - |
| Estimated EPS Next Report | -0.50 |
| Estimates Count | 5 |
| EPS Growth Next 5 Years % | 5.10 |
| Volume Overview | |
|---|---|
| Volume | 490.70K |
| Shares Outstanding | 54.48K |
| Shares Float | 44.73M |
| Trades Count | 2.20K |
| Dollar Volume | 538.37K |
| Avg. Volume | 488.57K |
| Avg. Weekly Volume | 449.10K |
| Avg. Monthly Volume | 451.20K |
| Avg. Quarterly Volume | 565.43K |
Cara Therapeutics Inc. (NASDAQ: CARA) stock closed at 1.13 per share at the end of the most recent trading day (a 7.62% change compared to the prior day closing price) with a volume of 490.70K shares and market capitalization of 61.56M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 80 people. Cara Therapeutics Inc. CEO is Derek T. Chalmers.
The one-year performance of Cara Therapeutics Inc. stock is -91.48%, while year-to-date (YTD) performance is -89.48%. CARA stock has a five-year performance of -92.97%. Its 52-week range is between 0.9 and 12.8, which gives CARA stock a 52-week price range ratio of 1.93%
Cara Therapeutics Inc. currently has a PE ratio of -6.40, a price-to-book (PB) ratio of 3.11, a price-to-sale (PS) ratio of 14.00, a price to cashflow ratio of 25.00, a PEG ratio of -1.25, a ROA of -43.80%, a ROC of -44.43% and a ROE of -49.13%. The company’s profit margin is 17.76%, its EBITDA margin is -227.00%, and its revenue ttm is $38.61 Million , which makes it $0.72 revenue per share.
Of the last four earnings reports from Cara Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.50 for the next earnings report. Cara Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Cara Therapeutics Inc. is Moderate Buy (1.75), with a target price of $22.33, which is +1 876.11% compared to the current price. The earnings rating for Cara Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cara Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cara Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.04, ATR14 : 0.11, CCI20 : 44.50, Chaikin Money Flow : -0.21, MACD : -0.08, Money Flow Index : 47.33, ROC : 2.73, RSI : 50.00, STOCH (14,3) : 88.46, STOCH RSI : 1.00, UO : 54.72, Williams %R : -11.54), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cara Therapeutics Inc. in the last 12-months were: Christopher A. Posner (Sold 5 987 shares of value $58 134 ), Frederique Menzaghi (Sold 16 034 shares of value $129 485 ), Goncalves Joana (Sold 18 220 shares of value $152 791 ), Joana Goncalves (Sold 18 489 shares of value $176 953 ), Menzaghi Frederique Ph.D. (Sold 2 993 shares of value $10 505 ), Posner Christopher (Sold 22 150 shares of value $142 465 ), Scott M. Terrillion (Sold 11 298 shares of value $101 790 ), Terrillion Scott (Sold 11 220 shares of value $81 642 )
Cara Therapeutics Inc.
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
CEO: Derek T. Chalmers
Telephone: +1 203 406-3700
Address: 107 Elm Street, 9th Floor, Stamford 06902, CT, US
Number of employees: 80
